The CimaVax vaccine was developed for NSCLC and it targets the EGFR overexpression. My daughters tumor tested negative for EGFR mutations. What effect does it have for EGFR positive mutations? Is the EGFR mutation even related to the vaccine? The article posted on Medscape says it targets EGFR overexpression found on approximately 40% to 80% of NSCLC. So how does one know if their cancer overexpresses EGFR and how much?
The CimaVax vaccine is not specifically directed at tumors with activating EGFR mutations. EGFR overexpression can be tested by staining the tumor tissue using a process known as immunohistochemistry (IHC).
Though this vaccine has shown promise in trials performed in Cuba, many experts in the rest of the world are waiting for more concrete proof of its efficacy, and trials in the U.S. and other locations are just beginning, so it may be some time before we have convincing evidence.
Jul 2008 Wife Liz (51/never smoker) Dx Stage IV NSCLC EGFR exon 19
4 cycles Carbo/alimta, 65% shrinkage
Mar 2010 progression, added Alimta, stable
Sep 2010 multiple brain mets, WBR
Oct 2010 large pericardial effusion, tamponade
Jan 2011 progression, start abraxane
Jun 2011-New liver, brain mets, add Tarceva
Oct 2011-Dx Leptomeningeal carcinomatosis; pulsed Tarceva
At rest Nov 4 2011
Since then: http://cancergrace.org/blog/jim-and-lisa